GenVec is an entrepreneurial clinical-stage biopharmaceutical company focused on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product, CGF166, is licensed to Novartis and currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, the company also licenses its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Location: United States, Maryland, Gaithersburg
Founded date: 1992
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Canaan Par... | canaan.com |
Mentions in press and media 2
| Date | Title | Description |
| 26.09.2016 | Can a Pill Fix Your Hearing? | Listen up, baby boomers (and others): Your damaged hearing may soon be improved—and it won’t require inserting a beige gizmo in your ear. Advances in molecular biology and bioinformatics have led to an explosion of research on the causes of... |
| 06.06.2007 | Patients, CEOs and ideologues vs. evidence-based medicine | The first time you hear it, “evidence-based medicine” sounds like one of those goofily redundant phrases like “animated cartoon” or “past experience.” Aren’t doctors always carrying out studies of one sort or another? Isn’t medicine evidenc... |